A Phase 3 clinical trial involving insulin glargine has been updated to completed status as of August 11, 2026. The study, registered as NCT04760626, is titled "A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before."
The trial compares insulin icodec, a weekly insulin used with the DoseGuide app, against daily insulins, including insulin glargine, in people with type 2 diabetes who had not previously used insulin. The status change to completed indicates that the study has concluded its planned activities as of the listed date.
No results have been reported in this update, and no efficacy or safety outcomes are described in the available data. The trial record on ClinicalTrials.gov reflects only the phase, status, and title as provided. Insulin glargine remains an approved treatment for diabetes management. Readers can consult the compound overview for additional background on insulin glargine.